Every intervention Outliyr has scored for acute pain relief, ranked by its BioHarmony score for this use case rather than its overall rating. The number beside each name is how well that one thing works for acute pain relief; the tier beside it is what it is worth once safety, cost and effort are counted across everything else.
38 of 104 evaluated interventions score 3.0+ out of 10 for acute pain relief · 5 comparisons
Lima 2024 reports Verified audit Track 1 source; six clinical trials with positive diabetic-foot-ulcer signals and considerable risk-of-bias caveats. Chang 2024 points in the same direction, but route, dose, baseline status, and…
Fan 2024 found low-level laser therapy reduced knee osteoarthritis pain with an SMD of 0.96, albeit with low certainty. Acute pain responds best when inflammation, soft-tissue irritation, or joint flare is the…
The evidence points to a plausible use case without proving a universal response. Derry S, Moore RA 2013 is the best anchor here because it reports 10 studies and 1,785 participants and…
Knee OA and postoperative-pain data support PEMF for short-term pain relief, especially when the device targets the injured or inflamed tissue. Bagnato 2016 supports knee OA symptom relief, and Hackel 2025 found…
Panebianco et al. 2022 gives the strongest anchor. gammaCore-class cervical nVNS has the clearest acute pain use case in migraine, with Tassorelli 2018 showing early pain-freedom advantages in episodic migraine. The score…
Hamaya 2025 anchors the strongest signal. The existing rationale points to this narrower claim: Acute pain relief is mostly from vasodilation, muscle relaxation, warmth, and reduced perceived stiffness. this verified source supports…
Chiu 2016 anchors the most relevant signal. Magnesium fits acute pain when low intake, stress load, mineral loss, or a form-specific target makes deficiency correction plausible. The score stays bounded because effects…
BFR can reduce pain during low-load rehab and may create short-term hypoalgesia, but pain relief is secondary to the training stimulus. The score stays bounded because Blood-Flow Restriction Training evidence for acute…
Vasireddi 2025 anchors the most relevant signal. BPC-157 fits acute pain when the target is tissue repair, vascular recruitment, or inflammation control, but the case still rests mostly on preclinical models. The…
Pain relief is not a core neurofeedback strength. Alpha-theta and central modulation protocols may help some users change pain salience, but acute pain endpoints are not where the evidence is strongest. Treat…
Jamialahmadi 2024 reports 7 trials; reported reductions in total cholesterol, triglycerides, and LDL, with no significant HDL change. Ye 2026 points in the same direction, but route, dose, baseline status, and outcome…
Acute-pain effects are likely secondary to faster tissue recovery, lower inflammation, or increased confidence during rehab. There is no direct acute-pain study for TB-500. The score remains below the injury-recovery score for…
The meta-analysis Qu 2018 pooled 12 RCTs (n=575) and found CoQ10 significantly reduced muscle pain, weakness, cramp, and tiredness, though creatine kinase did not change. The honest counterweight is Taylor 2015, a…
Studies show only modest, indirect analgesic effects. Whole-Body Vibration may improve circulation and reduce muscle soreness, but it does not act as a primary pain reliever. A recent meta-analysis found anti-inflammatory responses…
Soh 2024 anchors the most relevant signal. Glycine fits acute pain because glycine participates in sleep signaling, glutathione, collagen, methylation, and nervous-system balance, depending on the endpoint. The score stays bounded because…
Semaglutide is not an analgesic, anesthetic, anti-spasm agent, or injury treatment. Bliddal 2024 supports knee osteoarthritis improvement in obesity, but that is chronic load-related pain, not acute pain relief. The neutral score…
No direct acute-pain evidence was verified. EAAs support repair nutrition but are not analgesics.
Acute pain is not a primary keto indication. Migraine and inflammatory-pain anecdotes exist, and ketones may affect neuroinflammation, but RCT evidence is sparse. Some users improve because weight, glucose, and systemic inflammation…
No acute-pain evidence. Ca-AKG is not an analgesic.
INSUFFICIENT_EVIDENCE for acute pain; PEARL pain signals were subgroup and not an analgesia trial.
Acute pain may improve in injury, burn, or CRPS-related contexts where hyperbaric exposure reduces inflammation and supports tissue oxygenation. Kiralp 2004 reports CRPS pain and function changes. HBOT is not a primary…
Vagal activation has analgesic properties in experimental pain models.
Cramps can improve when dehydration or sodium loss is causal. The v0 pickle-juice and magnesium-cramp citations were not verified in audit, so this rating stays conservative.
Acute-pain remains low because any analgesic effect is indirect through inflammation and tissue repair. Pickart 2018 mentions anti-pain activity in protective-action framing, but no acute-pain RCT supports routine use.
No acute analgesic evidence supports metformin. It should not be used as an acute pain tool.
Acute-pain evidence improved after v0 but remains route-specific. Zhang 2025 and hemorrhoidectomy meta-analyses support local injection for postoperative pain, not oral microdose pain relief; the preserved v0 score remains conservative.
Electrical stimulation can gate pain acutely in targeted TENS-like settings, but WB-EMS is not mainly an acute analgesic protocol. For pain, stronger support is in chronic nonspecific low back pain rather than…
Retatrutide is not an acute pain drug. Any pain relief is downstream of slower weight loss and joint-load reduction, which does not match the timeline or mechanism of analgesic interventions.
Acute pain is not a Tβ4 mechanism; the peptide is a repair and migration regulator, not an analgesic. No human acute-pain trial exists and none should be expected.
Weak and inconsistent human evidence for acute pain specifically; most pain signal is in chronic, combined-cannabinoid contexts rather than acute CBD-alone use.
Tirzepatide is not an acute analgesic. It may not help acute pain. It can complicate perioperative settings through delayed gastric emptying and nausea. Score low and flag anesthesia or deep sedation as…
Exercise-induced hypoalgesia may occur during and shortly after sessions. Acute orthopedic pain can worsen if modality selection is poor.
Zone 2 is not an acute pain intervention. Some people feel better after easy movement, but pain relief is slower and less predictable than with targeted rehab, heat, mobility, or clinician-directed treatment.
Anti-inflammatory mechanism only. Not a direct analgesic and no strong acute-pain RCT base.
Some joint products report early pain changes, but exact rapid-onset claims were not fully verified in this audit. Collagen peptides are not useful for acute non-joint pain.
Omega-3 is too slow for acute pain. Any analgesic effect generally needs weeks of membrane incorporation and inflammation modulation.
Anti-inflammatory mechanism only; no human acute-pain trials for fucoidan.
Algafly 2007 British Journal of Sports Medicine showed surface cooling reduced sensory and motor nerve conduction velocity and raised pain threshold and tolerance during cold exposure (n=10, ankle ice immersion). Cold-induced analgesia…
Nothing matches those filters.
Monthly out-of-pocket cost at the most accessible legitimate channel, at the dose the score was given for. 15 of 38 are not priced yet; those cells are left blank rather than guessed.
| Intervention | Monthly cost | At dose | How you get it |
|---|---|---|---|
| Ozone Therapy | $520–$2,600 | 20-30 mcg/mL ozone, roughly 1,000-1,500 mcg total per session | In clinic |
| Red Light Therapy | $17–$43 | 10-20 min at 6-12 inches, full chest/face/back rotation | Over the counter |
| Celebrex (Celecoxib) | Not priced yet | ||
| PEMF (Pulsed Electromagnetic Field Therapy) | $3–$117 | 20-30 min mat session | Over the counter |
| Vagus Nerve Stimulation | $4–$8 | 10-20 min auricular tVNS at comfortable perceptible intensity | Over the counter |
| Infrared Sauna | $36–$73 | 55-60 degrees C, 20-30 min | Over the counter |
| Magnesium | $10–$20 | 200-400 mg glycinate elemental | Over the counter |
| Blood-Flow Restriction Training | Not priced yet | ||
| BPC-157 | $40–$80 | 250 to 500 mcg SC 1 to 2x/day near injury site | Grey market |
| Neurofeedback | Not priced yet | ||
| Molecular Hydrogen | Not priced yet | ||
| TB-500 (Thymosin Beta-4 Fragment) | Not priced yet | ||
| Coenzyme Q10 (CoQ10 / Ubiquinol) | $15–$40 | 100-200 mg/day | Over the counter |
| Whole-Body Vibration | $50–$100 | 30 Hz, roughly 0.3g, 10-20 min standing | Over the counter |
| Glycine | $2–$3 | 3 g oral glycine | Over the counter |
| Semaglutide | $199–$349 | 0.25 mg weeks 1 to 4, 0.5 mg weeks 5 to 8, 1.0 mg weeks 9 to 12, 1.7 mg weeks 13 to 16, 2.4 mg week 17 onward | Prescription |
| Essential Amino Acids | Not priced yet | ||
| Ketogenic Diet | $100 | Standard keto, 40-50 g total carbohydrate/day | Over the counter |
| Ca-AKG (Calcium Alpha-Ketoglutarate) | $15–$30 | 1 g/day generic Ca-AKG oral | Over the counter |
| Rapamycin | $15–$50 | 3 mg | Prescription |
| Hyperbaric Oxygen Therapy | $3,000–$6,000 | 2.0 ATA for 90 minutes with air breaks | In clinic |
| HRV Biofeedback | $5 | 20 min/session at individual RF (4.5 to 6.5 bpm) | Over the counter |
| Electrolytes | Not priced yet | ||
| GHK-Cu | $30–$100 | 0.5-3% topical serum or cream | Over the counter |
| Metformin | $4–$30 | 500 mg with dinner for 1 week, then 500 mg twice daily for 1 week, then increase by 500 mg/week toward 1000 mg twice daily as tolerated | Prescription |
| Methylene Blue | $13–$40 | 0.5-5 mg oral | Over the counter |
| Full-Body EMS | Not priced yet | ||
| Retatrutide | $130–$960 | 2 mg, then 4 mg, then 8 mg or 12 mg weekly depending on protocol and tolerability | Research use only |
| Thymosin Beta-4 (Tβ4) | Not priced yet | ||
| Full-Spectrum Hemp (CBD) | Not priced yet | ||
| Tirzepatide | $299–$449 | 2.5 to 5 to 7.5 to 10 to 12.5 to 15 mg | Prescription |
| Norwegian 4×4 | Not priced yet | Over the counter | |
| Zone 2 Cardio | Not priced yet | Over the counter | |
| Astaxanthin | Not priced yet | ||
| Collagen Peptides | $8–$40 | 2.5-10 g hydrolyzed collagen peptides | Over the counter |
| Omega-3 | $20–$40 | 1-2 g/day combined EPA+DHA | Over the counter |
| Fucoidan (Brown Seaweed Polysaccharide) | Not priced yet | ||
| Cold Plunge | Not priced yet | Over the counter |
Head-to-head reports and category rankings that name a winner on this use case.
BPC-157 for structural repair, KPV for inflammation you cannot afford to stimulate. BPC-157 scores gut health 9.0–9.5/10 against KPV's 7.0–7.5/10 and wins nearly every other row, because it…
CoQ10 scores 7.0–7.5/10 and methylene blue 6.0–6.5/10, yet methylene blue wins eleven of the seventeen shared use cases. The overall gap is risk, not effect. Methylene blue inhibits…
Magnesium glycinate is magnesium bound to glycine, so if you take it you already take both. That kills the question for sleep. The real decision: magnesium scores higher…
Red light therapy scores 7.5–8.0/10 and PEMF 7.5–8.0/10, so the panel is the better first buy for most people. PEMF wins on bone and joint pain, where a…
HBOT scores 5.5–6.0/10 and ozone 5.0–5.5/10, but ozone wins several use cases outright. Pick HBOT for wounds, cognition and neuro recovery, at $3,000 to $6,000 a month. Pick…
Ozone Therapy, at 8.0–8.5 out of 10 for acute pain relief. Lima 2024 reports Verified audit Track 1 source; six clinical trials with positive diabetic-foot-ulcer signals and considerable risk-of-bias caveats.
Of the top-scoring options, Glycine is the least expensive at about $2 a month, scoring 5.0–5.5 out of 10 for acute pain relief.
38 of the 104 interventions evaluated for acute pain relief score 3.0 out of 10 or better, which is the cut-off for appearing on this page.
